These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 2119417

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC.
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [Abstract] [Full Text] [Related]

  • 3. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH, Dreyer M, Dammann HG, Ditschuneit H.
    Med Klin (Munich); 1991 Mar 15; 86(3):142-8. PubMed ID: 1903497
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.
    Hoogerbrugge N, Mol MJ, Van Dormaal JJ, Rustemeijer C, Muls E, Stalenhoef AF, Birkenhäger JC.
    J Intern Med; 1990 Sep 15; 228(3):261-6. PubMed ID: 2119419
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun 14; 153(11):1321-9. PubMed ID: 8507122
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W, Bimmermann A, Schleicher J.
    Arzneimittelforschung; 1990 Dec 14; 40(12):1322-7. PubMed ID: 2128866
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R, Noseda G.
    Eur J Clin Pharmacol; 1990 Dec 14; 39(2):101-5. PubMed ID: 2123791
    [Abstract] [Full Text] [Related]

  • 9. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.
    Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Bondjers G.
    Lancet; 1990 Jun 09; 335(8702):1360-3. PubMed ID: 1971660
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
    Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, Margolis S, Dobs AS, Mellies MJ, Insull W.
    Atherosclerosis; 1990 Nov 09; 85(1):81-9. PubMed ID: 2126437
    [Abstract] [Full Text] [Related]

  • 11. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.
    Crepaldi G, Baggio G, Arca M, Avellone G, Avogaro P, Bittolo Bon G, Bompiani GD, Capurso A, Cattin L, D'Alŏ G.
    Arch Intern Med; 1991 Jan 09; 151(1):146-52. PubMed ID: 1898694
    [Abstract] [Full Text] [Related]

  • 12. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
    Wierzbicki AS, Lumb PJ, Cheung J, Crook MA.
    QJM; 1997 Oct 09; 90(10):631-4. PubMed ID: 9415344
    [Abstract] [Full Text] [Related]

  • 13. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
    Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, Hayashi H, Ito H, Yamamoto M, Takeuchi I.
    Atherosclerosis; 1988 Aug 09; 72(2-3):205-11. PubMed ID: 3145746
    [Abstract] [Full Text] [Related]

  • 14. [Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia].
    Arntz HR, Bönner G, Kikis D, Kirch W, Klör HU, Lederle RM, Overlack A, Steinmetz A, Stumpe KO.
    Dtsch Med Wochenschr; 1991 Jan 04; 116(1):7-12. PubMed ID: 1898717
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
    Nakaya N, Homma Y, Tamachi H, Shigematsu H, Hata Y, Goto Y.
    JAMA; 1987 Jun 12; 257(22):3088-93. PubMed ID: 3108527
    [Abstract] [Full Text] [Related]

  • 17. Clinical experience with simvastatin compared with cholestyramine.
    Erkelens DW, Baggen MG, Van Doormaal JJ, Kettner M, Koningsberger JC, Mol MJ.
    Drugs; 1988 Jun 12; 36 Suppl 3():87-92. PubMed ID: 3254824
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E, Muratti EN, Eliav O, Meiner V, Eisenberg S, Dann EJ, Sehayek E, Peters TK, Stein Y.
    Am J Med; 1994 May 12; 96(5):401-7. PubMed ID: 8192170
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
    Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, Brescia D.
    Clin Pharmacol Ther; 1990 Aug 12; 48(2):201-7. PubMed ID: 2116260
    [Abstract] [Full Text] [Related]

  • 20. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR.
    J Lab Clin Med; 1989 Sep 12; 114(3):250-9. PubMed ID: 2504855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.